Vis enkel innførsel

dc.contributor.authorRutagwera, David Gatsinzien_US
dc.contributor.authorMolès, Jean-Pierreen_US
dc.contributor.authorKankasa, Chipepoen_US
dc.contributor.authorMwiya, Mwiyaen_US
dc.contributor.authorTuaillon, Edouarden_US
dc.contributor.authorPeries, Marianneen_US
dc.contributor.authorNagot, Nicolasen_US
dc.contributor.authorVan de Perre, Philippeen_US
dc.contributor.authorTylleskär, Thorkilden_US
dc.date.accessioned2020-08-06T10:38:16Z
dc.date.available2020-08-06T10:38:16Z
dc.date.issued2019
dc.PublishedRutagwera DG, Molès J, Kankasa C, Mwiya M, Tuaillon E, Peries M, Nagot N, Van de Perre P, Tylleskär T. Prevalence and determinants of HIV shedding in breast milk during continued breastfeeding among Zambian mothers not on antiretroviral treatment (ART): A cross-sectional study. Medicine (Baltimore, Md.). 2019;98(44):e17383eng
dc.identifier.issn0025-7974
dc.identifier.issn1536-5964
dc.identifier.urihttps://hdl.handle.net/1956/23511
dc.description.abstractThe risk of postnatal HIV transmission exists throughout the breastfeeding period. HIV shedding in breast milk beyond six months has not been studied extensively. The aim of this study was to determine prevalence and determinants of HIV shedding in breast milk during continued breastfeeding A cross-sectional study was nested in the PROMISE-PEP trial in Lusaka, Zambia to analyze breast milk samples collected from both breasts at week 38 post-partum (mid-way during continued breastfeeding). We measured concurrent HIV deoxyribonucleic acid (DNA) and HIV ribonucleic acid (RNA) as proxies for cell-associated HIV (CAV) and cell-free HIV (CFV) shedding in breast milk respectively. Participants’ socio-demographic date, concurrent blood test results, sub clinical mastitis test results and contraceptive use data were available. Logistic regression models were used to identify determinants of HIV shedding in breast milk (detecting either CAV or CFV). The prevalence of HIV shedding in breast milk at 9 months post-partum was 79.4% (95%CI: 74.0 – 84.0). CAV only, CFV only and both CAV and CFV were detectable in 13.7%, 17.3% and 48.4% mothers, respectively. The odds of shedding HIV in breast milk decreased significantly with current use of combined oral contraceptives (AOR: 0.37; 95%CI: 0.17 – 0.83) and increased significantly with low CD4 count (AOR: 3.47; 95%CI: 1.23 – 9.80), unsuppressed plasma viral load (AOR: 6.27; 95%CI: 2.47 – 15.96) and severe sub-clinical mastitis (AOR: 12.56; 95%CI: 2.48 – 63.58). This study estimated that about 80% of HIV infected mothers not on ART shed HIV in breast milk during continued breastfeeding. Major factors driving this shedding were low CD4 count, unsuppressed plasma viral load and severe sub-clinical mastitis. The inverse relationship between breast milk HIV and use of combined oral contraceptives needs further clarification. Continued shedding of CAV may contribute to residual postnatal transmission of HIV in mothers on successful ART.en_US
dc.language.isoengeng
dc.publisherWolters Kluwereng
dc.rightsAttribution CC BYeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0eng
dc.titlePrevalence and determinants of HIV shedding in breast milk during continued breastfeeding among Zambian mothers not on antiretroviral treatment (ART): A cross-sectional studyen_US
dc.typePeer reviewed
dc.typeJournal article
dc.date.updated2020-01-28T11:57:11Z
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2019 The Author(s)
dc.identifier.doihttps://doi.org/10.1097/md.0000000000017383
dc.identifier.cristin1764681
dc.source.journalMedicine (Baltimore, Md.)


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY